Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose ATG and PTCy for GvHD Prophylaxis in Haplo-PBSCT
NCT03608059Phase 4Completed
- Sponsor
- Shanghai General Hospital
- Start
- Jul 2018
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of antithymocyte globulin rabbit, cyclophosphamide in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Shanghai General Hospital. Started Jul 2018; status: completed.
02
Drugs
antithymocyte globulin rabbitcyclophosphamide
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03608059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608059.